에 대한 최신 뉴스 CervoMed (NASDAQ:CRVO) 주식

CervoMed

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

News

Eurozone

Intraday Update

Markets

Trading Ideas

CMRX

CPIX

CRVO

QURE

YEXT

미국 주식은 미국 동부 시간 오후 2시에 혼조세를 보였으며, S&amp;P 500 지수는 화요일 약 0.1% 하락했다. 다우 지수는 0.02% 하락한 44,393.25로 거래되었고, 나스닥 지수는 0.03% 상승한 19,743.54로 거래되었다. S&amp;P 500 지수 또한 0.06% 하락하여 6,049.44로 거래되었다.

뉴욕 오후 2시 시황: S&amp;P 500 소폭 하락, 오토존, 부진한 1분기 실적 발표

CervoMed Inc

Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) ("Greenwave" or the "Company"), today announced that its margins have expanded significantly due to surging prices for scrap steel –&nbsp; already up 20% since early February and expected to go higher – ahead of steel and aluminum import tariffs taking effect on March 12, 2025.
&nbsp;
Prices for Scrap Steel have Surged More than 20% the Past Month and are Expected to Go Higher
Greenwave operates 13 metal recycling facilities in Virginia, North Carolina, and Ohio, providing 100% domestically-sourced scrap metal to Nucor, Sims, Cleveland-Cliffs, Georgia-Pacific, alongst other industry titans.
Unlike country-specific tariffs which are often modified, metal import tariffs significantly strengthen America's national security and are expected to remain in effect for the foreseeable future.
Fortress of Licenses: A Competitive Moat
Greenwave&nbsp;holds a portfolio of highly coveted operational licenses for the Company's metal recycling facilities.&nbsp;These licenses, often protected by grandfathered municipal codes, provide significant barriers to entry to competitors in Greenwave's tightly regulated markets.
Key highlights include:
<ul>
<li>Norfolk, VA Facility: Positioned near the largest U.S. Naval Base, Greenwave's&nbsp;Norfolk&nbsp;facility benefits from a steady influx of prime scrap metal and holds one of the only Virginia Department of Motor Vehicles automotive recycler/demolisher licenses in the city.</li>
<li>Virginia Beach, VA Facility: Greenwave operates the sole metal recycling facility in the state's largest city,&nbsp;Virginia Beach, strategically located directly across the street from NAS Oceana Master Jet Base and the region's thriving industrial core.</li>
<li>Portsmouth, VA Facility: A cost-effective hub for domestic and international shipments due to its proximity to the Port of&nbsp;Virginia, the Company's&nbsp;Portsmouth&nbsp;facility holds a license protected by grandfathered regulations.</li>
</ul>
Positioning for a Strategic Transaction Greenwave recently acquired the real estate for seven of its core facilities –&nbsp;thus&nbsp;reducing the Company's annual rent expenses by approximately&nbsp;$1.7 million,&nbsp;enhancing cashflow and positioning the Company for&nbsp;potential high-value strategic transactions.
Upcoming Growth Catalysts Greenwave is set to benefit from the 2025 opening of&nbsp;Nucor Corporation's&nbsp;state-of-the-art steelmaking facility&nbsp;in&nbsp;Lexington,&nbsp;North Carolina(1).&nbsp;The facility's staggering&nbsp;430,000-ton annual processing capacity, consisting of nearly 100% recycled materials, will significantly increase regional demand for recycled steel(1).
Greenwave stands as&nbsp;one of&nbsp;North Carolina's&nbsp;largest suppliers of recycled steel, operating five metal recycling facilities and an industry-leading American Pulverizer 60x85 shredder.&nbsp;The Company has a proven track record of supporting Nucor's operations,&nbsp;supplying its&nbsp;Hertford&nbsp;mill with steel for critical applications, including bridges, heavy equipment, and warships vital to American national security interests, including the&nbsp;$13 billion&nbsp;USS Gerald Ford aircraft carrier

GWAV

Greenwave Expands Margins as Steel Prices Jump, Boosted by Naval Scrap Supply and Nucor Demand, Eyes Tariff Windfall and Strategic Deals

<h3>Companies Reporting Before The Bell</h3>
• Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) is expected to report quarterly earnings at $0.89 per share on revenue of $305.85 million. 
• BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $1.15 billion. 
• UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) is estimated to report quarterly loss at $0.72 per share on revenue of $25.25 million. 
• DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is expected to report quarterly loss at $0.14 per share on revenue of $7.39 million. 
• Fennec Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $16.42 million. 
• Optical Cable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) is estimated to report earnings for its first quarter. 
• Cohen &amp; Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/COHN#AMEX">COHN</a>) is expected to report earnings for its fourth quarter. 
• Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) is projected to report quarterly loss at $3.67 per share on revenue of $433 thousand. 
• Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) is estimated to report earnings for its fourth quarter. 
• Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) is expected to report earnings for its fourth quarter. 
• Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $25.55 million. 
• NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) is likely to report earnings for its fourth quarter. 
• Willis Lease Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) is estimated to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Ramaco Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METCB#NASDAQ">METCB</a>) is projected to report earnings for its fourth quarter. 
• Ramaco Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $176.04 million. 
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $215.50 million. 
• One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) is expected to report quarterly earnings at $0.28 per share on revenue of $239.77 million. 
• NCS Multistage Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCSM#NASDAQ">NCSM</a>) is likely to report earnings for its fourth quarter. 
• Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) is projected to report quarterly loss at $0.03 per share on revenue of $1.62 million. 
• Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) is projected to report earnings for its fourth quarter. 
• Douglas Elliman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) is expected to report quarterly loss at $0.08 per share on revenue of $233.65 million. 
• Great Elm Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GECC#NASDAQ">GECC</a>) is expected to report quarterly earnings at $0.35 per share on revenue of $11.46 million. 
• Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $9.90 million. 
• Greenlight Capital Re (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) is projected to report earnings for its fourth quarter. 
• Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) is likely to report quarterly earnings at $1.49 per share on revenue of $14.39 billion. 
• Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) is likely to report quarterly loss at $0.18 per share on revenue of $43.88 million. 
• Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) is likely to report quarterly loss at $0.18 per share on revenue of $75.58 million. 
• TruBridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBRG#NASDAQ">TBRG</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $84.38 million. 
• Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $384.99 million. 
• Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) is likely to report quarterly loss at $0.07 per share on revenue of $158.36 million. 
• Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $59.40 million. 
• LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $57.34 million. 
• Seaport Entertainment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SEG#AMEX">SEG</a>) is likely to report earnings for its fourth quarter. 
• Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) is likely to report quarterly earnings at $0.77 per share on revenue of $149.37 million. 
• PLAYSTUDIOS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $67.73 million. 
• Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $23.78 million. 
• System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) is expected to report quarterly loss at $0.23 per share on revenue of $91.28 million. 
• Mission Produce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $272.00 million. 
• StandardAero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SARO#NYSE">SARO</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $1.37 billion. 
• Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $222.06 million. 
• HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $246.32 million. 
• PGIM ETF Trust PGIM Portfolio Ballast ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/PBL#BATS">PBL</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $147.18 million. 
• Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $121.19 million. 
• Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) is projected to report quarterly earnings at $6.36 per share on revenue of $1.14 billion. 
• Mobile Infrastructure (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) is likely to report earnings for its fourth quarter. 
• Auna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUNA#NYSE">AUNA</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $296.50 million. 
• Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) is expected to report quarterly loss at $0.01 per share on revenue of $187.84 million. 
• Flotek Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTK#NYSE">FTK</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $50.08 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGS

ASAN

AUNA

Mobile Infrastructure Corporation Common Stock

BEEP

BNTX

CHRS

COHN

CVGI

DOUG

DRIO

FENC

GAIA

GECC

GLRE

HSAI

LCTX

LFMD

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MYPS

NCSM

NPWR

ORCL

RAND

SARO

STKS

SUPV

TBRG

URGN

WLFC

YALA

Earnings Scheduled For March 10, 2025

The Company intends to use the net proceeds of any sales of Common Shares under the ATM Program for the production of all-electric vehicles, including BEAST school buses and EV Star commercial vehicles, as well as for product development, with the remainder, if any, for general corporate purposes.
 &nbsp;

Reported Friday, GreenPower Enters Sales Agreement With Roth Capital For $850K ATM Offering To Fund BEAST And EV Star EV Production

At week 24, 42.3% of patients in the higher dose group achieved ≥75% reduction from baseline in Eczema Area and Severity Index score (EASI-75), a 29.5% difference vs. placebo (p &lt; 0.001). In the lower dose group, 36.3% of patients achieved EASI-75, a 23.4% difference vs. placebo (p &lt; 0.001).
In the higher dose group, 23.6% of patients achieved a validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-ADTM) score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baseline (vIGA-AD 0/1) at week 24, representing a 14.9% difference vs. placebo (p &lt; 0.001). In the lower dose group, 19.1% of patients achieved this endpoint, a 10.3% difference vs. placebo (p = 0.002).
In addition, IGNITE met the endpoint of revised Investigator's Global Assessment (rIGATM) score of 0/1 with a ≥2-point reduction from baseline, a more stringent measure of efficacy than vIGA-AD 0/1. At week 24, 22.7% of patients in the higher dose group achieved this endpoint, a 14.4% difference vs. placebo (p &lt; 0.001). In the lower dose group, 16.3% of patients achieved this endpoint, an 8.0% difference vs. placebo (p = 0.01).

AMGN

Reported Saturday, Amgen And Kyowa Kirin's Rocatinlimab Delivers Up To 42.3% EASI-75 Response At Week 24 In Phase 3 IGNITE Trial

The Company reported an operating loss of $2.1 million ($0.08 per share) versus a $3.4 million loss in the same quarter of 2023 ($0.18 per share).
The operating loss for the full year 2024 was $8.8 million ($0.35 per share) versus $18.5 million ($1.01 per share) in 2023.
CEO Thomas DeRosa noted that AppTech underwent significant organizational changes in the fourth quarter when a new investor group committed $5 million to improve the Company's operations; established voting control of the Board of Directors and replaced certain key executives including the CEO and CFO. New CFO Felipe Corrado stated "We are encouraged by the organizational and operating improvements made in the fourth quarter. We bolstered our capital position, reduced expenses and narrowed our focus solely to several potentially near-term and profitable customers."

APCX

Reported Friday, Apptech Posted Q4 Loss Of $0.08 Per Share, Up From Loss Of $0.18 Per Share YoY, Signaling Continued Progress On Cost Efficiency And Capital Reinforcement

The Trump administration is reportedly in discussions with four different groups regarding&nbsp;the sale of the Chinese short video platform, TikTok.
What Happened: On Sunday, U.S. President Donald Trump confirmed that his administration was communicating with four different groups regarding the sale of TikTok, reported Reuters. TikTok&#8217;s future has been uncertain since a Biden-administration law, that requires its owner, ByteDance, to either sell the platform on national security grounds by Apr 5 or risk a ban, came into effect on Jan 19.
President Trump, after assuming office on Jan. 20, signed an executive order aiming to postpone the law&#8217;s enforcement by 75 days. When asked if a deal on TikTok was imminent, Trump told reporters while on board Air Force One, &#8220;It could.&#8221; 
&#8220;We&#8217;re dealing with four different groups, and a lot of people want it &#8230; all four are good,&#8221; he added.
Although ByteDance has not expressed any interest in selling TikTok's U.S. operations, CEO Chew Shou Zi met with Trump at Mar-a-Lago in December and was also present at his inauguration ceremony.
SEE ALSO: <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44212362/bitcoin-ethereum-and-dogecoin-crash-as-trump-refuses-to-rule-out-recession-arthur-hayes-predicts-btc-to-retest-78000">Bitcoin, Ethereum And Dogecoin Crash As Trump Refuses To Rule Out Recession: Arthur Hayes Predicts BTC To Retest $78,000</a>
Why It Matters: The potential sale of TikTok comes amid growing tensions between the U.S. and China over data security. The uncertainty at TikTok has also attracted several potential buyers, including Frank McCourt, former owner of the Los Angeles Dodgers. McCourt&#8217;s bid for TikTok&#8217;s U.S. operations has been bolstered by the addition of Reddit Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) co-founder and venture capitalist Alexis Ohanian as a strategic adviser for Project Liberty, <a href="https://www.benzinga.com/general/social-media/25/03/44100560/reddit-co-founder-alexis-ohanian-joins-frank-mccourts-tiktok-bid-amid-competition-from-mrbeast-jesse-tinsley-and-reid-rasner">known as &#8220;The People&#8217;s Bid&#8221;</a>.  
YouTube&nbsp;star&nbsp;MrBeast and tech entrepreneur Jesse Tinsley are some of the other bidders. Notably, Trump has also suggested the name of Larry Ellison, the founder of Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>). Analysts estimate the fast-growing business&nbsp;could be worth as much&nbsp;as $50 billion.
Interestingly, Elon Musk, the owner of the X social network, has stated that he is not interested.
Trump&#8217;s comments come on the heels of TikTok <a href="https://www.benzinga.com/markets/emerging-markets/25/02/44040537/tiktok-invests-8-8-billion-in-thailand-data-centers-bypassing-us-china-tech-tensions">committing $8.8 billion </a>in data centers in Thailand over five years, bypassing US-China tech tensions.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/03/44213521/us-economic-slowdown-talk-of-the-town-says-economist-mohamed-el-erian-as-fed-chair-powell-reaffirms-growth-at-solid-pace">US Economic Slowdown &#8216;Talk Of The Town,&#8217; Says Economist Mohamed El-Erian As Fed Chair Powell Reaffirms Growth At &#8216;Solid Pace&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

RDDT

US Courts New Buyers For TikTok As Deal Deadline Approaches: 'All Four Are Good,' Says Trump

Logility previously announced on January 24, 2025 that it had entered into a definitive agreement to be acquired by Aptean, Inc. ("Aptean") for $14.30 per share in an all-cash transaction (the "Aptean Merger Agreement"). The Logility Board of Directors has determined that the Unsolicited Proposal would reasonably be expected to lead to a superior proposal under the terms of the Aptean Merger Agreement. As a result of the Logility Board of Directors' determination, Logility may, under the terms of the Aptean Merger Agreement, engage in discussions with the unsolicited bidder based on the Unsolicited Proposal and Logility intends to do so.
The Aptean Merger Agreement remains in full force and effect, and the Logility Board of Directors reaffirms its existing recommendation that Logility's shareholders vote in favor of the transaction with Aptean.

LGTY

Reported Friday, Logility Confirms $15.00 Unsolicited Offer Under Review; Board Says Proposal May Be Superior To Aptean Agreement

<ul>
<li>Projects aim to be responsive to the energy needs of data centers by offering an abundant supply of operational power within two years</li>
<li>Projects target the provision of on-site, continuous, and scalable power generation, and securing data center uptime even in volatile market conditions</li>
<li>The partnership would involve innovative capital structuring coupled with environmental credit cash flow generation from the fuel cell platforms and coal mine methane (CMM)</li>
<li>Clean fuel cell technology can reduce the carbon footprint of data center and other high-volume electrical off-takers</li>
<li>Projects aspire to create jobs and other economic benefits focused on the Appalachian region</li>
</ul>

FCEL

Diversified, FuelCell Energy And TESIAC Form Acquisition And Development Company T Deliver Net-Zero Power For Data Centers

CONSOLIDATED NET REVENUES (UNAUDITED)
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Jan</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Sequential</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">YoY</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(NT$ Million)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">44,961</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">49,444</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">39,751</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-9.1&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">+13.1&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Jan</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Sequential</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">YoY</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(US$ Million)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1,374</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1,506</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1,269</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-8.8&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">+8.3&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
Net revenues for ATM assembly, testing and material business are as follows:
ATM NET REVENUES (UNAUDITED)
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Jan</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Sequential</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">YoY</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(NT$ Million)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">27,332</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">28,137</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">23,291</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-2.9&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">+17.3&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Jan</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Feb</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Sequential</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">YoY</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(US$ Million)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Change</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">835</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">857</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">744</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-2.5&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">+12.3&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>

ASE Technology Reported February 2025 Revenue Of $1.37B, Up 8.3% YoY; ATM Revenue Of $835M, Up 12.3% YoY

Billionaire investor Chamath Palihapitiya believes a proposed 10% cap on credit card interest rates would significantly disrupt the financial services industry while potentially benefiting consumers.
What Happened: &#8220;This would be phenomenally disruptive,&#8221; Palihapitiya wrote Sunday on X. &#8220;Would force everyone who can embrace ultra low cost rails to emerge. Incumbents would be in trouble for sure.&#8221;
Palihapitiya was responding to news that Congresswoman Anna Luna (R-FL) is working with Rep. Alexandria Cortez (D-NY) on legislation to cap credit card interest rates at 10%.
His comments come as President Donald Trump and Sen. Bernie Sanders (I-VT) have independently supported similar proposals. Sanders announced plans to introduce legislation <a href="https://www.benzinga.com/markets/equities/24/12/42737402/bernie-sanders-supports-trumps-credit-card-interest-rate-cap-at-10-amid-highest-defaults-since-2008-visa-and-mastercard-trade-in-the-red">backing Trump&#8217;s 10% cap idea</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This would be phenomenally disruptive. <a href="https://t.co/3mb8fZfyh3">https://t.co/3mb8fZfyh3</a>
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1898778255332905401?ref_src=twsrc%5Etfw">March 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I think opposite. Would force everyone who can embrace ultra low cost rails to emerge. Incumbents would be in trouble for sure.
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1898790966091489749?ref_src=twsrc%5Etfw">March 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The initiative gains significance as credit card defaults reach their highest levels since the 2008 financial crisis. U.S. credit card lenders wrote off $46 billion in seriously delinquent loan balances during the first nine months of 2024, a 50% increase year-over-year, <a href="https://www.benzinga.com/24/12/42721109/mark-cuban-once-said-credit-card-users-dont-want-to-be-rich-now-us-credit-card-defaults-have-skyrocketed-to-highest-levels-since-2008-financial-crisis">according to BankRegData</a>.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/25/03/44212386/stock-futures-drop-as-reverse-trump-trade-takes-holdpeter-schiff-says-market-shift-long-overdue-and-will-likely-continue-for-a-decade" target="_blank" rel="noreferrer noopener">Stock Futures Drop As ‘Reverse Trump Trade&#8217; Takes Hold—Peter Schiff Says Market Shift ‘Long Overdue&#8217; And Will Likely Continue For A Decade</a>
Why It Matters: While Palihapitiya acknowledged he &#8220;generally hate[s] price controls,&#8221; he expressed support for &#8220;ultra low cost rails in financial services.&#8221; His view contrasts with industry warnings that such caps could restrict credit access for lower-income Americans.
Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), the nation&#8217;s third-largest credit card lender, reported its credit card write-off rate increased to 6.1% in November, up from 5.2% a year ago.
The current average credit card interest rate stands at 21.5%, according to Federal Reserve data, <a href="https://www.benzinga.com/personal-finance/24/09/41024812/trumps-bold-plan-limit-credit-card-interest-rates-to-10-but-could-this-move-lead-to-dangerous-pr">more than double the proposed cap</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44212672/jamie-dimon-cashed-out-234-million-in-jpmorgan-stock-warren-buffett-stockpiled-334-billion-in-cash-weeks-later-markets-crashed-coincidence" target="_blank" rel="noreferrer noopener">Jamie Dimon Cashed Out $234 Million In JPMorgan Stock, Warren Buffett Stockpiled $334 Billion In Cash — Weeks Later, Markets Crashed. Coincidence?</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Economics

Chamath Palihapitiya Calls Proposed 10% Credit Card Interest Rate Cap 'Disruptive' As Trump, Sanders, And Lawmakers Push For Reform

Valens Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>), a leader in high-performance connectivity,&nbsp;today&nbsp;announced that it will display its innovative connectivity technology required for various AI applications at Embedded World 2025. Valens will display demonstrations in collaboration with a variety of companies, all offering the machine vision market cutting-edge solutions based on Valens' standard-compliant chipsets. These companies include Leopard Imaging, Acroname, Airy3D, Cherry Embedded Solutions, D3 Embedded, Fabrimex, Framos, Intel, RGo Robotics, and Teledyne e2v.

INTC

Valens Teams With Intel, Teledyne, and Others to Power Next-Gen Machine Vision Solutions, To Showcase AI-Driven Connectivity Tech at Embedded World 2025

VMAR

Vision Marine Technologies Announced The Filing Of A New Patent Application With Kennedy Lenart Spraggins, For Adaptive Control Of A Water Pump In A Marine Propulsion System

<ul>
<li>ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus</li>
<li>Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0</li>
<li>ESK-001 was generally well-tolerated at one year, with no new safety findings</li>
<li>Data further support ESK-001's potential to offer a highly differentiated and best-in-class treatment option for people with moderate-to-severe plaque psoriasis
<ul>
<li>Phase 3 ONWARD program ongoing with topline data expected in Q1 2026</li>
</ul>
</li>
</ul>

ALMS

Reported Saturday, Alumis' ESK-001 Demonstrates Sustained PASI 90 And PASI 100 Responses At Week 52 In Phase 2 Psoriasis Study

<ul>
<li>Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm</li>
<li>Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD</li>
<li>Topline results from Phase 3 ICONIC-ADVANCE 1&amp;2&nbsp;studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO</li>
<li>These results pave the way to initiate the first-ever head-to-head study seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe plaque PsO</li>
</ul>

Reported Saturday, Johnson & Johnson's Icotrokinra Achieves Complete Skin Clearance In 46% Of Patients At Week 24, Showing Potential To Redefine Psoriasis Treatment

Economist Mohamed El-Erian highlighted the risks of an economic slowdown as Federal Reserve Chairman Jerome Powell reiterated that the economy was growing at a &#8220;solid pace&#8221; during his Friday address at the University of Chicago.
What Happened: During a podcast with Forward Guidance, the chief economic advisor at Allianz, El-Erian underscored &#8220;two disturbing data&#8221; sets on the stagflation side.
This included a fall in February&#8217;s ISM Manufacturing New Orders Index, which contracted to 48.6% after expanding for three months, indicating a weakening demand and a decline in new orders compared to the previous month.
The other data set highlighted by El-Erian included February&#8217;s job report, wherein nonfarm payrolls increased by 151,000 and the unemployment rate rose to 4.1%, the highest in 3.5 years, thus inducing uncertainty in the labour market. However, &#8220;one qualification is the slip in labor force participation,&#8221; from 62.6% to 62.4%, according to him.
&#8220;So the concern that we all have, is that while growth is slowing down, companies will feel that they need to pass on the higher costs into higher prices, of course that&#8217;s why tariffs play a major role because people are worried that it won&#8217;t be a once and for all effect, it may be a repeated effect, so there&#8217;s a price level and then there&#8217;s an inflation effect,&#8221; he said.
Economic slowdown was &#8220;the talk of the town,&#8221; El-Erian said while highlighting lower oil prices, negative stock futures, lower yields, and a weaker dollar on Monday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The possibility of lower US economic growth is now the talk of the town, amplified by this weekend's remarks from high-level officials. As you would expect, the market impact so far this early morning in Asian trading includes lower oil prices (with Brent again joining WTI below… <a href="https://t.co/egyftI2GpR">pic.twitter.com/egyftI2GpR</a>
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1898950253325279263?ref_src=twsrc%5Etfw">March 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, President Donald Trump did not rule out a recession this year, acknowledging potential short-term turbulence from his economic agenda but expressing confidence in future prosperity. In a Fox News interview, he said, "I hate to predict things like that" and called the changes "very big."
See Also: <a href="https://www.benzinga.com/government/regulations/25/03/44160833/us-dollar-weakness-a-symptom-not-cause-argues-expert-as-economist-hails-devaluation-to-restore-global-growth">US Dollar Weakness A &#8216;Symptom Not Cause,&#8217; Argues Expert As Economist Hails Devaluation To &#8216;Restore Global Growth&#8217;</a>
Why It Matters: Despite the looming uncertainties and the difficulty of businesses to chart their way forward, Fed Chair Powell <a href="https://www.federalreserve.gov/newsevents/speech/powell20250307a.htm">said</a>, &#8220;The U.S. economy continues to be in a good place.&#8221;
He reaffirmed that the labor market is solid, and inflation has moved closer to the 2% longer-run goal. &#8220;At the Federal Reserve, we are intently focused on the dual-mandate goals given to us by Congress: maximum employment and stable prices,&#8221; Powell said.
Outlining the future course of action, he said that if inflation doesn&#8217;t fall to the 2% goal, the Fed will maintain policy restraint for longer and if the labor market weakens, the Fed will ease the policy accordingly.
Talking about the rate cuts, El-Erian added that he sees one cut and not three cuts in 2025 because of the persistent inflation and how the Fed is unlikely to &#8220;look through&#8221; that issue, the way they did in 2021.
Price Action: Futures of the Dow Jones slipped to 0.38%, whereas S&amp;P 500 and Nasdaq 100 declined by 0.49% and 0.61% respectively. Crude Oil WTI Futures dropped 0.51% to $66.7, the dollar index spot was down to the 103.816 level and the 10-year Treasury bonds yielded 4.29% as of 2:18 a.m., EDT.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, advanced on Friday. SPY gained 0.56% to $575.92, and QQQ was up 0.74% to $491.79, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44159401/rigetti-claims-leadership-in-quantum-computing-race-aims-to-scale-to-100-qubits-as-it-looks-to-catch-up-with-ibm-google">Rigetti Asserts &#8216;Leadership&#8217; In Quantum Computing Race, Aims To Scale To 100 Qubits As It Looks To Catch Up With IBM, Google</a></li>
</ul>
Photo courtesy: Federal Reserve

Government

Market Summary

Federal Reserve

US Economic Slowdown 'Talk Of The Town,' Says Economist Mohamed El-Erian As Fed Chair Powell Reaffirms Growth At 'Solid Pace'

<ul>
<li>Low disease activity was observed after a mean duration of 80 consecutive days off-treatment following success with VTAMA cream, with a mean weekly Peak Pruritus Numerical Rating Scale (PP-NRS) score of 2.9 at the end of the treatment-free interval</li>
<li>Data presented as late breaker at 2025 American Academy of Dermatology (AAD) Annual Meeting</li>
</ul>

Reported Saturday, Organon's VTAMA Phase 3 Data Shows 84% Of Patients Maintained Mild Disease After 80-Day Off-Treatment Interval In Adults And Children 2+

<ul>
<li>Significantly more patients treated with Sotyktu achieved ACR and PASI response rates and had greater improvements in patient-reported quality of life compared with placebo at Week 16</li>
<li>Sotyktu was well-tolerated in comparison with placebo and apremilast, demonstrating safety consistent with its established clinical profile</li>
</ul>

Reported Saturday, Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Showing Sotyktu Superior To Placebo In Psoriatic Arthritis

<ul>
<li>Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study</li>
<li>Topline results from Phase 3 ICONIC-ADVANCE 1&amp;2studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe PsO</li>
<li>Results pave the way to initiate the first-ever head-to-head study (ICONIC-ASCEND) seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe PsO</li>
</ul>

PTGX

Reported Saturday, Protagonist Reports Icotrokinra Achieved IGA 0/1 In 74% Of Patients At Week 24 With Favorable Safety Profile

Four Canadian stores of&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) have been suspected of exploiting the country&#8217;s EV rebate program. The stores are said to have sold an average of 30&nbsp;cars per hour over three days, claiming&nbsp;over 50% of the&nbsp;remaining rebate funds.
What Happened: Four Tesla stores in Canada managed to sell an average of 30 cars per hour, amounting to 120 cars per hour across all four locations, as <a href="https://www.thestar.com/news/canada/tesla-gamed-the-system-canadian-auto-dealers-stiffed-millions-when-u-s-giant-rushed-to/article_6d1025c6-fa0a-11ef-b780-a73277202cb2.html">reported </a>by the Toronto Star on Friday. 
This sales boom lasted for three consecutive days, even during hours when the stores were supposedly closed. Reportedly, a total of 8,653 cars were sold during the final 72 hours of the EV rebate program, also known as the iZEV Program.
Consequently, the Elon Musk-led company applied&nbsp;for C$43.1 million ($30 million) in&nbsp;rebates, which is over&nbsp;half of the remaining C$71.8&nbsp;million ($50 million) allocated for EV&nbsp;rebates.
The iZEV rebate program provided incentives ranging from C$2,500 ($1740.29) to C$5,000 ($3480.57) for purchasing electric vehicles and plug-in hybrids. Dealerships applied the rebate directly to the purchase price, anticipating reimbursement from the government.
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
As a result of the incident, the rival brands haven&#8217;t been able to access the EV credits as Tesla claimed more than half of them. The Canadian Automobile Dealers Association (CADA), has received rebate claims for 2,295 electric vehicles from 226 dealers who are yet to receive the reimbursement, resulting in a collective shortfall of C$10 million.
CADA&#8217;s spokesperson, Huw Williams, told the Toronto Star, "Somehow, Tesla gamed the system. What we can't figure out is how this could have happened without setting off alarm bells."
Notably, Transport Canada, the body which oversees the iZEV rebate program, has not clarified whether any wrongdoing took place. It also stated that there is no restriction preventing Tesla from submitting rebate paperwork in bulk after delivering sold cars.
SEE ALSO: <a href="https://www.benzinga.com/news/25/03/44211240/warren-buffett-on-debt-and-donald-trumps-money-moves-trump-never-went-right">Warren Buffett on Debt and Donald Trump&#8217;s Money Moves: Trump &#8216;Never Went Right&#8217;</a>
Why It Matters: Tesla has been struggling in Canada, wherein thousands of Canadians have even signed a petition for revoking Musk&#8217;s Canadian citizenship. According to&nbsp;data from shop4tesla.com, the EV maker&#8217;s sales in Canada have dropped by approximately 70% between December 2024 and January 2025.
This surge in sales comes on the heels of Tesla&#8217;s recent offer of lifetime free supercharging for new Foundation Series Cybertruck purchases in Canada. Tesla <a href="https://www.benzinga.com/tech/25/03/44160193/tesla-offers-lifetime-free-supercharging-on-foundation-series-cybertruck-purchases-in-canada-mexico">announced this offer </a>to make the expensive truck more appealing to customers. The offer, valid for orders placed on or after March 5, lasts for the duration of the customer's ownership of the vehicle and is non-transferable.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/25/03/44212993/palantir-ceo-alex-karp-meets-hyundai-vice-chair-to-enhance-ai-shipyard-defense-collaboration-amid-trumps-call-for-us-shipbuilding-revival">Palantir CEO Alex Karp Meets Hyundai Vice Chair to Enhance AI Shipyard, Defense Collaboration Amid Trump&#8217;s Call for US Shipbuilding Revival</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

TSLA

Tesla Suspected Of EV Rebate Manipulation In Canada Amid Sudden Sales Surge Before Deadline: 'Tesla Gamed The System', Says Industry Body

<ul>
<li>Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) --</li>
<li>Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggestive of potential for remittive effect; multiple inbound patient requests to re-initiate dosing --</li>
<li>In the Phase 2a clinical trial, bempikibart was observed to be safe and well-tolerated, with PK supporting subcutaneous dosing and receptor occupancy data demonstrating desired target engagement; clinical biomarkers showed changes in Th2 biomarkers, and expected on-mechanism changes in T-cells, indicative of potent IL-7 and TSLP inhibition --</li>
<li>Bempikibart development program remains on track with open-label extension study to initiate in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 --</li>
</ul>

QTTB

Reported Saturday, Q32 Bio Presents Phase 2a Data Showing Bempikibart Induces Sustained Hair Regrowth Post-Treatment In Severe Alopecia Areata

Press Releases

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Management

CervoMed Announces Key Senior Leadership Appointments

Health Care

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Clinical Trial Results Show Positive Signs For Potential New Dementia Treatment

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

General

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

ABVC BioPharma

Allakos

BioAtla

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

GlycoMimetics

Geovax Labs

HCW Biologics

HOOKIPA Pharma

IN8bio

Longeveron

Leap Therapeutics

Lisata Therapeutics

MEI Pharma

Marker Therapeutics

Nanoviricides

NextCure

Palatin Techs

SAB Biotherapeutics

Senti Biosciences

Synlogic

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Tenax Therapeutics

D. Boral Capital

Canaccord Genuity

Roth MKM

Morgan Stanley

Brookline Capital

Screenshot 2024-11-26 at 7.00.24 PM

Biotech

Interview

미국 주식은 미국 동부 시간 오후 2시에 혼조세를 보였으며, S&amp;P 500 지수는 화요일 약 0.1% 하락했다.
다우 지수는 0.02% 하락한 44,393.25로 거래되었고, 나스닥 지수는 0.03% 상승한 19,743.54로 거래되었다. S&amp;P 500 지수 또한 0.06% 하락하여 6,049.44로 거래되었다.
주요 섹터 동향
화요일에 통신 서비스 주식이 2.3% 상승했다.
반면, 화요일에는 부동산 주식이 1% 하락했다.
주요 뉴스
화요일에 오토존(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>)은 1분기 실적이 예상보다 저조하게 나타났다고 발표했다.
이 회사는 주당 순이익이 $32.52로, 시장 예상치인 $33.76을 하회했으며, 분기 매출이 $42억 8천만(+2.1% 전년 대비)으로 분석가 컨센서스인 $43억에 못 미쳤다.
주가 상승 종목
<ul>
<li>키메릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) 주식이 213% 급등하여 $2.71로 거래되었다. 이는 회사가 재발성 H3 K27M-변이 확산성 교모세포종 환자를 위한 도르다비프론(dordaviprone)의 가속 승인 신청을 제출할 것이라고 발표한 후 발생한 일이다.</li>
<li>또한, 컴벌랜드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) 주식이 94% 급등하여 $2.4001로 거래되었다. 이는 회사가 FDA로부터 아세타도트(acetadote)에 대한 보충 신약 신청이 승인되었다고 발표한 후 발생한 일이다.</li>
<li>유니큐어 N.V.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) 주식도 상승하였으며, 129% 상승하여 $16.71로 거래되었다. 이는 회사가 AMT-130에 대한 가속화 경로의 주요 요소에 대해 FDA와 합의했다고 발표한 후 발생한 일이다.</li>
</ul>
주가 하락 종목
<ul>
<li>서보메드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) 주식이 77% 하락하여 $2.34로 거래되었다. 이는 회사가 네플라마피모드(Neflamapimod)의 2b 단계 시험이 치매 치료를 위한 주요 목표를 달성하지 못했다고 발표한 후 발생한 일니다.</li>
<li>이엑스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) 주식이 17% 하락하여 $7.07로 거래되었다. 이는 회사가 3분기 실적을 발표한 후 발생한 일이다.</li>
<li>메디롬 헬스케어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) 주식이 46% 하락하여 $1.52로 거래되었다. 메디롬 헬스케어 테크놀로지스는 286만 개의 미국 예탁증서(ADS)에 대한 500만 달러 공모가를 주당 1.75달러에 책정했다.</li>
</ul>
원자재 상품 시장
상품 뉴스에 따르면, 원유 가격이 0.7% 상승하여 $68.84로 거래되었고, 금 가격이 1.2% 상승하여 $2,718.80로 거래되었다.
은 가격은 0.4% 상승하여 $32.73으로 거래되었고, 구리 가격은 0.1% 하락하여 $4.2730으로 거래되었다.
유로존
유럽 주식은 오늘 하락 마감했다. 유로존의 STOXX 600 지수가 0.52% 하락했으며, 독일의 DAX 지수가 0.08% 하락하고, 프랑스의 CAC 40 지수가 1.14% 하락했다. 스페인의 IBEX 35 지수는 0.38% 하락했으며, 런던의 FTSE 100 지수는 0.86% 하락했다.
아시아 태평양 시장
아시아 시장은 월요일에 혼조세로 마감되었다. 일본의 닛케이 225 지수는 0.18% 상승했고, 홍콩의 항셍 지수는 2.76% 상승했다. 중국의 상하이 종합 지수는 0.05% 하락했으며, 인도의 BSE 센섹스는 0.25% 하락했다.
경제 지표
미국 비농업 사업 부문 노동 생산성이 3분기에 2.2% 증가하여 예비치와 일치했다.
지금 읽어보세요:
<ul>
<li><a href="https://www.benzinga.com/24/12/42412458/amazon-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday">아마존이 약 15% 상승할까요? 화요일을 위한 10개의 주요 애널리스트 예측</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

뉴욕 오후 2시 시황: S&P 500 소폭 하락, 오토존, 부진한 1분기 실적 발표

Comments

CervoMed

뉴스

에 대한 최신 뉴스 CervoMed (NASDAQ:CRVO) 주식

화요일, 12월 10, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌